Nebilet (Nebivolol)

Nebivolol blocks β1‑adrenergic receptors in the heart, decreasing heart rate and contractility. It also stimulates endothelial nitric‑oxide production, causing vasodilation. The combined effect reduces cardiac output and peripheral resistance, leading to a sustained decrease in blood pressure.

The dose of Nebilet is individualized by the prescribing clinician based on the patient’s blood pressure, age, renal and hepatic function, and concomitant medications. The prescriber determines the appropriate starting dose and any subsequent titration.

Safety data for nebivolol during pregnancy and lactation are limited. It is classified as a drug with unknown pregnancy category, and the decision to use it should be based on a careful risk‑benefit assessment by the healthcare provider.

To order Nebilet, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nebilet (nebivolol) is a third‑generation β1‑selective blocker with additional nitric‑oxide‑mediated vasodilatory activity, which may result in fewer metabolic side effects compared with older non‑selective beta blockers. Its profile is often considered advantageous for patients who need both heart‑rate control and improved endothelial function.

Nebilet should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain stability and potency.

Nebilet is taken orally, usually once daily, with or without food as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious adverse events include severe bradycardia, heart block, marked hypotension, bronchospasm in patients with reactive airway disease, and rare cases of hepatic dysfunction or allergic reactions. Patients should seek immediate medical attention if they experience fainting, rapid weight gain, swelling, or difficulty breathing.

Nebilet is contraindicated in patients with known hypersensitivity to nebivolol or any excipients, those with severe bradycardia, second‑ or third‑degree atrioventricular block without a pacemaker, and individuals in cardiogenic shock. Caution is also advised for patients with uncontrolled asthma or severe chronic obstructive pulmonary disease.